Patrick Enright Acquires 5,882 Shares of Vera Therapeutics (NASDAQ:VERA) Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) Director Patrick Enright purchased 5,882 shares of the stock in a transaction that occurred on Thursday, December 11th. The stock was bought at an average price of $42.50 per share, with a total value of $249,985.00. Following the completion of the acquisition, the director owned 5,882 shares in the company, valued at $249,985. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Vera Therapeutics Stock Down 1.2%

NASDAQ:VERA traded down $0.59 during trading hours on Monday, hitting $49.21. The stock had a trading volume of 2,791,379 shares, compared to its average volume of 1,757,569. The company has a current ratio of 12.21, a quick ratio of 12.21 and a debt-to-equity ratio of 0.19. The business has a 50 day simple moving average of $32.42 and a two-hundred day simple moving average of $26.67. The company has a market cap of $3.15 billion, a PE ratio of -12.33 and a beta of 1.21. Vera Therapeutics, Inc. has a 1-year low of $18.53 and a 1-year high of $51.19.

Vera Therapeutics (NASDAQ:VERA) last announced its earnings results on Wednesday, November 5th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.06). During the same period last year, the firm earned ($0.85) earnings per share. Analysts predict that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.

Institutional Trading of Vera Therapeutics

Hedge funds have recently made changes to their positions in the business. Bollard Group LLC purchased a new stake in shares of Vera Therapeutics during the 2nd quarter valued at $1,509,000. Trexquant Investment LP increased its stake in Vera Therapeutics by 187.1% in the first quarter. Trexquant Investment LP now owns 62,777 shares of the company’s stock valued at $1,508,000 after acquiring an additional 40,913 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in Vera Therapeutics during the first quarter valued at about $326,000. Russell Investments Group Ltd. raised its position in Vera Therapeutics by 505.1% during the first quarter. Russell Investments Group Ltd. now owns 152,918 shares of the company’s stock valued at $3,673,000 after purchasing an additional 127,646 shares in the last quarter. Finally, EFG Asset Management North America Corp. lifted its stake in Vera Therapeutics by 49.4% during the first quarter. EFG Asset Management North America Corp. now owns 109,281 shares of the company’s stock worth $2,623,000 after purchasing an additional 36,121 shares during the last quarter. 99.21% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently commented on VERA shares. JPMorgan Chase & Co. decreased their target price on Vera Therapeutics from $53.00 to $52.00 and set an “overweight” rating on the stock in a report on Friday, November 7th. Pivotal Research set a $73.00 target price on shares of Vera Therapeutics in a research note on Friday, December 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Wednesday, October 8th. Bank of America initiated coverage on shares of Vera Therapeutics in a research note on Thursday, October 16th. They set a “buy” rating and a $48.00 price target on the stock. Finally, Cowen restated a “buy” rating on shares of Vera Therapeutics in a research report on Friday, December 5th. Ten investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Vera Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $66.58.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.